BioMarin Pharmaceuticals BMRN Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $105.53M— | —— | -$30.74M-113% | $240.53M+29.5% | $185.69M+48.6% | ||
| $16.41M-19.7% | $20.44M+10.6% | $18.49M-0.4% | $18.56M-15.9% | $22.07M-6.5% | ||
| $43.46M-7.4% | $46.91M-4.8% | $49.27M+3.6% | $47.53M+26.1% | $37.7M-27.4% | ||
| $9.22M+1,404% | $613K— | —— | $33.34M+17.3% | $28.43M-32.9% | ||
| $6.09M+832% | $653K+0.6% | $649K-1.7% | $660K0.0% | $660K0.0% | ||
| $0-100% | $122.05M— | —— | —— | $2.97M— | ||
| $7.16M-94.1% | $120.68M— | —— | $98.53M+71.1% | $57.59M— | ||
| -$44.49M-345% | $18.13M-31.1% | $26.33M-45.3% | $48.13M+97.8% | $24.34M-29.0% | ||
| $3.1M— | —— | $116.37M+1,918% | $5.77M+317% | -$2.66M+97.4% | ||
| -$1.48M-125% | $5.89M-69.3% | $19.17M+61.4% | $11.88M+632% | $1.62M-96.1% | ||
| $8.7M— | —— | $16.36M+372% | $3.47M+67.6% | $2.07M-54.3% | ||
| $5.37M+98.3% | $2.71M— | $0-100% | $649K-48.8% | $1.27M+106% | ||
| $11.55M+128% | -$41.02M-341% | $17.03M+94.3% | $8.77M+38.5% | $6.33M— | ||
| $220.65M+121% | $99.64M-73.0% | $368.69M+99.0% | $185.27M+6.2% | $174.39M-6.1% | ||
| $20.92M-48.6% | $40.72M+43.2% | $28.45M+66.3% | $17.1M+2.0% | $16.77M-14.1% | ||
| $25.79M-39.5% | $42.61M-61.6% | $110.83M-2.1% | $113.16M+26.8% | $89.27M+54.2% | ||
| $767.28M+1,674% | $43.25M-56.2% | $98.81M-16.2% | $117.93M+51.6% | $77.8M-49.7% | ||
| -$4.97M— | $0— | —— | —— | $0+100% | ||
| $725.53M+1,809% | -$42.45M+87.2% | -$330.96M-2,528% | -$12.59M+55.4% | -$28.24M-137% | ||
| $850M— | —— | —— | —— | $0— | ||
| $28.18M+944% | $2.7M+24.1% | $2.18M-82.3% | $12.31M-68.3% | $38.78M+690% | ||
| $8.65M— | —— | —— | —— | $0— | ||
| $813.17M— | $0+100% | -$2.17M+52.9% | -$4.6M+88.1% | -$38.78M— | ||
| $1.41M— | —— | —— | -$3.06M-116% | -$1.42M-157% | ||
| $1.76B+2,760% | $61.57M+69.7% | $36.29M-78.0% | $165.01M+55.7% | $105.96M-60.4% | ||
| $14.64M-43.7% | $26M+232% | $7.82M-85.0% | $52M+401% | $10.39M-51.0% | ||
| $455K-58.9% | $1.11M+13.1% | $978K-27.8% | $1.36M-0.5% | $1.36M-21.1% | ||
| $6.09M+832% | $653K+0.6% | $649K-1.7% | $660K0.0% | $660K0.0% | ||
| $0-100% | $122.05M— | —— | —— | $2.97M— | ||
| -$6.71M-59.2% | -$4.22M+24.1% | -$5.55M-17.6% | -$4.72M-147% | $10.03M— | ||
| $11.55M+128% | -$41.02M-341% | $17.03M+94.3% | $8.77M+38.5% | $6.33M— | ||
| $5.37M+98.3% | $2.71M— | $0-100% | $649K-48.8% | $1.27M+106% | ||
| -$4.97M— | $0— | —— | —— | $0+100% | ||
| $767.28M+1,674% | $43.25M-56.2% | $98.81M-16.2% | $117.93M+51.6% | $77.8M-49.7% | ||
| $8.65M— | —— | —— | —— | $0— | ||
| $850M— | —— | —— | —— | $0— | ||
| $4.48M— | —— | —— | —— | $0-100% | ||
| $199.73M+239% | $58.92M-82.7% | $340.24M+102% | $168.17M+6.7% | $157.63M-5.1% | ||
| $199.73M+239% | $58.92M-82.7% | $340.24M+102% | $168.17M+6.7% | $157.63M-5.1% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does BioMarin Pharmaceuticals generate?
- BioMarin Pharmaceuticals (BMRN) generated $874.3M in operating cash flow over the trailing twelve months.
- What is BioMarin Pharmaceuticals's free cash flow?
- After $107.2M of capital expenditures, BioMarin Pharmaceuticals's free cash flow was $767.1M over the trailing twelve months, up 22.9% year over year.
- Where does BioMarin Pharmaceuticals's cash flow data come from?
- Every line is extracted from BioMarin Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
